What is the appropriate dosing schedule and timing for estrogen and medroxyprogesterone acetate in hormone replacement therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Take Estrogen and Medroxyprogesterone for HRT: Dosing and Timing

For women with an intact uterus requiring hormone replacement therapy, administer transdermal 17β-estradiol continuously (50-100 μg daily via patches changed twice weekly) combined with oral medroxyprogesterone acetate 10 mg daily for 12-14 days every 28 days, or alternatively use continuous combined therapy with 2.5 mg medroxyprogesterone acetate daily. 1

Estrogen Administration

Route Selection

Transdermal estrogen is the preferred first-line route due to avoidance of hepatic first-pass metabolism, which reduces cardiovascular and thromboembolic risks—particularly important for women with hypertension, hypertriglyceridemia, or increased thrombosis risk 1. The 2021 guidelines specifically emphasize transdermal 17β-estradiol as first choice for women at higher cardiovascular risk 2.

Transdermal Dosing

  • Patches releasing 50-100 μg of 17β-estradiol per 24 hours
  • Change twice weekly or weekly depending on brand specifications 2
  • Administer continuously without interruption 2

Oral Alternative (Second Choice)

If transdermal route is contraindicated or refused:

  • 1-2 mg oral 17β-estradiol daily 2
  • Oral route has higher interindividual variability and hepatic effects 1

Medroxyprogesterone Acetate (MPA) Administration

All women with an intact uterus must receive progestogen for endometrial protection to prevent endometrial hyperplasia and cancer 1, 3.

Sequential (Cyclic) Regimen - Preferred for Younger Women

10 mg MPA orally for 12-14 days every 28 days 1, 2, 1

  • Induces predictable withdrawal bleeding
  • Provides adequate endometrial protection 1, 4
  • Example: Days 1-28 continuous estrogen, add MPA days 15-28 (or 15-26) 2

Key advantage: Recent evidence suggests cyclical administration may have lower cardiovascular and thromboembolism risk compared to continuous regimens 2

Continuous Combined Regimen - For Avoiding Withdrawal Bleeding

2.5 mg MPA orally daily (taken continuously with estrogen) 1

  • Achieves amenorrhea in 76-80% of women by 6 months 4, 5
  • By 24 months, 90-94% are amenorrheic 4
  • Approximately 42% experience breakthrough bleeding in first 3 months, decreasing over time 4

Alternative continuous dose: 5 mg MPA daily also provides endometrial protection 1, 6

Practical Regimen Examples

Option 1: Sequential Combined (Induces Monthly Bleeding)

  • Transdermal 17β-estradiol 50 μg patch continuously (change twice weekly)
  • Plus oral MPA 10 mg daily for days 15-28 of each 28-day cycle 2

Option 2: Continuous Combined (Avoids Bleeding)

  • Transdermal 17β-estradiol 50 μg patch continuously (change twice weekly)
  • Plus oral MPA 2.5 mg daily without interruption 2, 5

Option 3: Combined Patches (Best Compliance)

If available, use combined estradiol-progestin patches for improved adherence 2:

  • Sequential: 17β-estradiol alone for 2 weeks, then combined 17β-estradiol + levonorgestrel for 2 weeks
  • Continuous: Combined patches changed continuously without interruption

Important Clinical Considerations

Timing of Initiation

  • Optimal window: Within 10 years of menopause or before age 60 7, 8
  • Starting after age 65 increases cardiovascular and dementia risks 8, 9

Duration of Therapy

  • Continue until average age of natural menopause (45-55 years) for premature ovarian insufficiency 2
  • For standard menopause management: use lowest effective dose for symptom control 3, 10
  • The 2025 FDA removal of the "shortest duration" mandate allows individualized duration based on benefits and risks 7

Monitoring

  • Do NOT use FSH levels to monitor adequacy—they remain elevated despite adequate tissue effects 1
  • Monitor bone density with DEXA scans 1
  • Assess cardiovascular risk factors and lipid profiles 1

Common Pitfalls to Avoid

  1. Never use unopposed estrogen in women with intact uterus—this dramatically increases endometrial cancer risk 3, 10

  2. Insufficient progestogen duration: Must give progestogen for minimum 10-14 days monthly in sequential regimens 1, 3—shorter durations provide inadequate endometrial protection

  3. Starting too late: Initiating HRT after age 65 or >20 years post-menopause increases cardiovascular risks without the protective benefits seen with earlier initiation 8, 9

  4. Expecting immediate amenorrhea with continuous regimens: Counsel patients that 40-50% will have breakthrough bleeding in first 3-6 months, which typically resolves 4, 5

Women Without a Uterus (Post-Hysterectomy)

Use estrogen-only therapy without progestogen 10, 9:

  • Transdermal 17β-estradiol 50-100 μg daily continuously
  • Or oral conjugated equine estrogen 0.625 mg daily
  • No need for progestogen adds, which may increase breast cancer risk 9

References

Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2011

Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause: executive summary of recommendations.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2011

Research

Then and Now: What We Have Learned From the WHI.

The Journal of clinical endocrinology and metabolism, 2026

Research

Long-term hormone therapy for perimenopausal and postmenopausal women.

The Cochrane database of systematic reviews, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.